Faculty profile

Jean-Mathieu Beauregard

ResearcherUniversité Laval

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.

Jean-Mathieu Beauregard

Researcher

Health Sciences

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
15 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Artificial Intelligence Dosimetry Gpu Computing Molecular Imaging Personalized Medicine Position Emission Tomography Predictive/Prognostic Biomarkers Quantitative Spect

Latest papers

Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026 · senior author
How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?
European urology focus · 2026 · first author
The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study.
Cancer imaging : the official publication of the International Cancer Imaging Society · 2025 · senior author

All 44 publications

Latest funding

Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC
CIHR · 2025 · Co-investigator
$1,162,800
Rare Isotopes to Transform Cancer Therapy
SSHRC · 2022 · Co-investigator
$7,944,656
Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice
CIHR · 2021 · Nominated PI
$960,075

All 3 grants and awards

44 publications.

Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center.

Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, Fradet Y, Lacombe L, Lévesque É, Marcoux N, Toren P, April G, Arsenault F, Beaulieu A, Singbo N, Veilleux C, Tremblay-Boily M, Tremblay V, Buteau FA, Beauregard JM

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2026Senior author

DOI: 10.5489/cuaj.9398 PMID: 41701883

How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?

Beauregard JM, Ong M, Pouliot F

European urology focus2026First author

DOI: 10.1016/j.euf.2026.06.013 PMID: 42336749

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study.

Zamanian A, Rousseau É, Buteau FA, Arsenault F, Beaulieu A, April G, Juneau D, Plouznikoff N, Turcotte ÉE, Allard C, Richard PO, Saad F, Guérin B, Pouliot F, Beauregard JM

Cancer imaging : the official publication of the International Cancer Imaging Society2025Senior author

DOI: 10.1186/s40644-025-00910-z PMID: 40665456

Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.

Akhavanallaf A, Lu Z, Peterson AB, Blakkisrud J, Kurkowska S, Yadav S, Wang C, Uribe C, Stokke C, Rahmim A, Wong KK, Beauregard JM, Hope TA, Sjögreen Gleisner K, Dewaraja YK

Journal of nuclear medicine : official publication, Society of Nuclear Medicine2025

DOI: 10.2967/jnumed.124.269098 PMID: 40404396

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.

Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, Lévesque É, Castonguay V, Marcoux N, Lodde M, Juneau D, Hamilou Z, Lattouf JB, Buteau FA, Pavic M, Castilloux JF, Neveu B, Bouvet GF, Allard C, Tétu A, Guérin B, Beauregard JM, 3TMPO Investigators

Journal of nuclear medicine : official publication, Society of Nuclear Medicine2024Senior author

DOI: 10.2967/jnumed.124.268020 PMID: 39327017

Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.

Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, Haug A, Hicks RJ, Lenzo NP, Navalkissoor S, Nicolas GP, Pais B, Volteau M, Wild D, McEwan A, Lassmann M

European journal of nuclear medicine and molecular imaging2024

DOI: 10.1007/s00259-024-06682-1 PMID: 38528164

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.

Hansen AR, Probst S, Beauregard JM, Viglianti BL, Michalski JM, Tagawa ST, Sartor O, Tutrone RF, Oz OK, Courtney KD, Delpassand ES, Nordquist LT, Osman MM, Chi KN, Sparks R, George N, Hawley SM, Wu W, Jensen JD, Fleshner NE

Frontiers in oncology2024

DOI: 10.3389/fonc.2024.1483953 PMID: 39839782

Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [177Lu]Lu-DOTATATE radiopharmaceutical therapy.

Mansouri Z, Salimi Y, Akhavanallaf A, Shiri I, Teixeira EPA, Hou X, Beauregard JM, Rahmim A, Zaidi H

European journal of nuclear medicine and molecular imaging2024

DOI: 10.1007/s00259-024-06618-9 PMID: 38267686

A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.

Wild D, Grønbæk H, Navalkissoor S, Haug A, Nicolas GP, Pais B, Ansquer C, Beauregard JM, McEwan A, Lassmann M, Pennestri D, Volteau M, Lenzo NP, Hicks RJ

European journal of nuclear medicine and molecular imaging2023

DOI: 10.1007/s00259-023-06383-1 PMID: 37721581

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.

Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J

The Lancet. Oncology2023

DOI: 10.1016/s1470-2045(23)00158-4 PMID: 37269841

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2021

Subject: Prospective PhD student: Artificial Intelligence Dear Professor Beauregard, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice" (2021), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Jean-Mathieu Beauregard

Research

Latest papers

Latest funding

Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center.

How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study.

Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.

Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.

Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [177Lu]Lu-DOTATATE radiopharmaceutical therapy.

A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.

Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC

Rare Isotopes to Transform Cancer Therapy

Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice

Frequent collaborators

Vincent Fradet

Arman Rahmim

Carlos Uribe

Paul Toren

Michael Kolinsky

Michael Ong

Wassim Kassouf

Katherine Zukotynski

Gad Abikhzer

Robert Laforce

Fabrice Mac-Way